Interferon-statin combination therapy

• US 20030232033A1
• Filed: 02/20/2003
• Published: 12/18/2003
• Est. Priority Date: 02/21/2002
• Status: Active Grant

• Current Assignee: Stephen B. Cantrell
• Original Assignee: Stephen B. Cantrell
• Inventors: Cantrell, Stephen B.
• Granted Patent: US 9,034,310 B2
• Time in Patent Office: Days
• US Class Current: 424/85.5
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/21 Interferons [IFN]
• CPC Class Codes: A61K 38/212 IFN-alpha
• CPC Class Codes: A61K 38/215 IFN-beta
• CPC Class Codes: A61K 38/217 IFN-gamma

Abstract

A method for pharmacological treatment of cancer and other diseases is presented which includes the novel combination of a statin (Hmg-CoA reductase inhibitor, such as lovastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, pravastatin, or newer agents), with an interferon (such as interferon alfa-2b or others) or an angiogenesis inhibitor (a very similar and often overlapping group of drugs which inhibit blood vessel growth and maintenance, such as thalidomide, angiostatin, endostatin, or other agents), and also including concurrent administration of selenium and calcium. The method disclosed in this invention is useful because it can prove more effective than previously known therapies for certain diseases and because its use may be more tolerable, less disfiguring, and less expensive than other methods. The method here disclosed can be readily reproduced by any person skilled in the art of treating disease.

Claims

1. A method of pharmacologic treatment comprising the administration of a therapeutically effective amount of one or more Hmg-CoA reductase inhibitors and the administration of a therapeutically effective amount of one or more interferons.

2. A method according to claim 1 in which the Hmg-CoA reductase inhibitor employed may include one or more selected from the known group of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin, and any other pharmacologic agents useful for the inhibition of activity of Hmg-CoA reductase.

3. A method according to claim 1 in which the interferon employed may include one or more selected from the known group of interferon alfa-2a, alfa-2b, alfa-2c, alfa-n1, alfa-n3, beta interferon, gamma interferon, and any other pharmacologic agents classified as interferons.

4. A method of pharmacologic treatment comprising the administration of a therapeutically effective amount of one or more Hmg-CoA reductase inhibitors and the administration of a therapeutically effective amount of one or more agents effective for inhibition of the growth or maintenance of blood vessels.

5. A method according to claim 4 in which the angiogenesis inhibitor employed may include one or more selected from the known group of thalidomide, angiostatin, endostatin, amifostine, anginex, tumstatin, and any other pharmacologic agents demonstrated as angiogenesis inhibitors.

6. A method according to claim 4 in which the Hmg-CoA reductase inhibitor employed may include one or more selected from the known group of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin, and any other pharmacologic agents useful for the inhibition of activity of Hmg-CoA reductase.